<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and pathogenesis of systemic lupus erythematosus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and pathogenesis of systemic lupus erythematosus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and pathogenesis of systemic lupus erythematosus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter H Schur, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bevra H Hahn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The reported prevalence of systemic lupus erythematosus (SLE) in the United States is 20 to 150 cases per 100,000 [<a href="#rid1">1-5</a>]. In one meta-analysis, the prevalence was 73 out of 100,000. In women, prevalence rates vary from 164 (White individuals) to 406 (African American individuals) per 100,000 [<a href="#rid1">1</a>]. Due to improved detection of mild disease, the incidence nearly tripled in the last 40 years of the 20<sup>th</sup> century [<a href="#rid6">6</a>]. Estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe, and Asia [<a href="#rid2">2,7-9</a>].</p><p>Geography and race appear to affect the prevalence of SLE and the frequency and severity of clinical and laboratory manifestations:</p><p class="bulletIndent1"><span class="glyph">●</span>The disease appears to be more common in urban than rural areas [<a href="#rid1">1,10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, the prevalence of SLE is higher among Asian, African American, African Caribbean, and Hispanic American individuals compared with White individuals [<a href="#rid2">2,7,8,10</a>]. In European countries, the prevalence of SLE is also higher among individuals from Asia and Africa [<a href="#rid2">2</a>]. By comparison, SLE occurs infrequently in Africa [<a href="#rid2">2,11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Photosensitivity and discoid skin lesions may be more frequent clinical manifestations in patients with Northern European ancestry than those with Southern European ancestry; the former group is, however, less likely to have anticardiolipin and anti-double-stranded deoxyribonucleic acid (anti-dsDNA) antibodies [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Sex</span><span class="headingEndMark"> — </span>The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect [<a href="#rid13">13,14</a>] (see <a class="local">'Hormonal factors'</a> below). An estrogen effect is suggested by a number of observations, including the female-to-male ratio of SLE in different age groups:</p><p class="bulletIndent1"><span class="glyph">●</span>In children, in whom sex hormonal effects are presumably minimal, the female-to-male ratio is 3:1 [<a href="#rid15">15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In adults, especially in women of childbearing years, the ratio ranges from 7:1 to 15:1 [<a href="#rid1">1,15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In "older" individuals, especially post-menopausal women, the ratio is approximately 8:1 [<a href="#rid15">15</a>].</p><p></p><p>Factors related to the X chromosome may also be important in predisposing women to SLE. At least three predisposing gene variants are located on X chromosomes (IRAK1, MECP2, TLR7) [<a href="#rid16">16</a>]. There is also evidence for a gene dose effect, since the prevalence of XXY (Klinefelter's syndrome) is increased 14-fold in men with SLE when compared with the general population of men, whereas XO (Turner's syndrome) is underrepresented in women with SLE [<a href="#rid17">17</a>].</p><p>Other possibilities for female predisposition include: X-inactivation, imprinting, X or Y chromosome genetic modulators, differential methylation of DNA and acetylation of histones bound to DNA, intrauterine influences, chronobiologic differences, pregnancy, microchimerism following pregnancies, and menstruation [<a href="#rid18">18-20</a>].</p><p>However, it is important to note that SLE that occurs in men is slightly different clinically from that in women, and men tend to have worse outcomes [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Age at onset</span><span class="headingEndMark"> — </span>Sixty-five percent of patients with SLE have disease onset between the ages of 16 and 55 [<a href="#rid22">22</a>]. Of the remaining cases, 20 percent present before age 16 [<a href="#rid23">23</a>] and 15 percent after age 55 [<a href="#rid24">24</a>]. Median ages at diagnosis for White females range from 37 to 50 years, in White males from 50 to 59, in Black females from 15 to 44, and in Black males from 45 to 64 [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Factors affecting disease outcome</span><span class="headingEndMark"> — </span>Different epidemiologic subgroups (eg, race/ethnicity, sex, and age of onset) tend to have varying degrees of disease activity and may thus affect disease outcome:</p><p class="bulletIndent1"><span class="glyph">●</span>African American and Mexican Hispanic individuals in the United States have a poorer renal prognosis than White individuals, a finding not entirely independent of socioeconomic status [<a href="#rid25">25</a>]. African American individuals are more likely to have anti-Sm, anti-RNP, discoid skin lesions, proteinuria, psychosis, and serositis [<a href="#rid25">25-27</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical status is poorer in those with less education [<a href="#rid25">25,28</a>]; this effect may reflect poor compliance [<a href="#rid29">29</a>]. Clinical status is also poorer in those with lower socioeconomic status and with inadequate access to medical care [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The extent and degree of activity of SLE varies in different countries and in different ethnic groups [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Men with lupus tend to have higher frequencies of renal disease, skin manifestations, cytopenias, serositis, neurologic involvement, thrombosis, cardiovascular disease, hypertension, and vasculitis than women [<a href="#rid33">33</a>]. By contrast, Raynaud phenomenon, photosensitivity, and mucosal ulceration are less frequent manifestations in men than women. Most, but not all studies suggest that men have a higher one-year mortality rate [<a href="#rid33">33-38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SLE in children tends to be symptomatically more severe than in adults, with a high incidence of malar rashes, nephritis, pericarditis, hepatosplenomegaly, and hematologic abnormalities [<a href="#rid23">23,34</a>].</p><p></p><p>Lupus tends to be milder in older adults, who often have a presentation more similar to that of drug-induced lupus. Clinical features of lupus in older patients include the following [<a href="#rid34">34,39-41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A lower ratio of affected women to men than for younger patients</p><p class="bulletIndent1"><span class="glyph">●</span>Lower incidence of malar rash, photosensitivity, purpura, alopecia, Raynaud phenomenon, renal, central nervous system, and hematologic involvement</p><p class="bulletIndent1"><span class="glyph">●</span>Lower prevalence of anti-La, anti-Sm, and anti-RNP antibodies and of hypocomplementemia</p><p class="bulletIndent1"><span class="glyph">●</span>Greater prevalence of sicca symptoms, serositis, pulmonary involvement, and musculoskeletal manifestations</p><p class="bulletIndent1"><span class="glyph">●</span>Greater prevalence of rheumatoid factor</p><p></p><p class="headingAnchor" id="H6"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of systemic lupus erythematosus (SLE) remains unknown and is clearly multifactorial. This suggests that SLE may in fact be more than one disease, with many clinical symptoms and different pathophysiologic abnormalities. Thus, in the future, SLE and its variants may be classified by having the same genetic and biologic pathway abnormalities rather than based on clinical manifestations (eg, the American College of Rheumatology [ACR] criteria) and serologic abnormalities (such as the various types of antinuclear antibodies).</p><p>We present below what is known about the various genetic factors, hormonal factors, and environmental factors, and how they might interact to cause the syndrome we refer to as SLE.</p><p>To date, at least 100 susceptibility loci increase risk for polygenic multifactorial SLE, and 30 genes cause the monogenic form of SLE and SLE-like phenotype [<a href="#rid42">42</a>]. However, it is not clear how these "monogenic" defects lead to SLE. Furthermore, some of these genetic defects, such as complement deficiencies, have been found in individuals without SLE.</p><p>Etiology can be understood best if SLE is considered to be caused initially by immune pathways that lead to pathogenic autoantibodies. Some autoantibodies react with antigens such as nucleic acids, nucleosomes, phospholipids in cell membranes, and other nuclear and cytoplasmic antigens derived from dead cells, dying cells, and particles containing DNA. These autoantibodies either form immune complexes or bind directly to their antigens and subsequently cause immune/inflammatory reactions that lead to disease.</p><p class="headingAnchor" id="H3427981119"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Genome-wide association studies (GWAS) have identified over 100 gene loci with polymorphisms (or mutations or copy numbers) that predispose to polygenic SLE (the vast majority of cases) as well as more than 30 genes (mostly via mutations) causing monogenic forms of SLE or SLE-like phenotypes [<a href="#rid16">16,43-46</a>]. However, this genetic information accounts for only 30 to 40 percent of susceptibility to SLE, suggesting a large component of environmental or epigenetic influences or undiscovered gene alterations. Genetic factors that confer the highest hazard ratios (HR) of 5 to 25 are deficiencies of the complement components C1q (required to clear apoptotic cells), C4A and B, C2, or the presence of a mutated <em>TREX1</em> gene (encodes the 3’ repair endonuclease 1 enzyme that degrades DNA). Each of these causes monogenic disease (defined as SLE patients who carry high-penetrance either dominantly or recessively inherited pathogenic variants in a single gene [<a href="#rid42">42</a>]); they are relatively rare in the population. A heterozygous mutation in the <em>TREX1</em> gene has been associated with familial chilblain lupus [<a href="#rid47">47</a>]. Similarly, polymorphism in other DNA repair genes (<em>ATG5</em>, <em>DNASE1</em>) predispose to SLE [<a href="#rid16">16,42</a>]. Several monogenic lupus or lupus-like diseases are associated with interferonopathy and affect the levels of, or pathways in, the interferon (IFN) system, particularly type 1. These include TNFAIP3, ribonuclease (RNase) H2A-H2B, IFIH1, and several others [<a href="#rid42">42</a>].</p><p>The most common genetic predisposition is found at the major histocompatibility (MHC) locus. The MHC contains genes for antigen-presenting molecules (class I human leukocyte antigens [HLA-A, -B, and -C] and class II HLA molecules [HLA-DR, -DQ, and -DP]) (see  <a class="medical medical_review" href="/d/html/3987.html" rel="external">"Human leukocyte antigens (HLA): A roadmap"</a>). The MHC also contains genes for some complement components, cytokines, and heat shock protein.</p><p>Predisposing loci, which include HLA-DR2 and HLA-DR3, are associated with HR of approximately 1.2 to 2.4, but the region is complex and involves multiple gene linkages across the entire 120-gene region in multiple ethnic groups [<a href="#rid48">48,49</a>]. Within HLA-DRB1 loci, HLA-DRB1*0301 and HLA-DRB1*1501 predispose to SLE, whereas HLA-DRB1*1401 reduces risk. The HR for predisposing HLA-DR/DQ is approximately 2.4 and is increased in patients homozygous for predisposing alleles, indicating a gene dose effect. HR for other genes varies from 1.2 to 2.3, with additional reports of significant, but relatively low HR-conferring, genes occurring at a rapid pace.</p><p>Other genes with predisposing variants involve some associated with innate immunity (<em>IRF5</em>, <em>STAT4</em>, <em>IRAK1</em>, <em>TNFAIP3</em>, <em>SPP1</em>, <em>TLR7</em>), most of which are associated with IFN-alpha pathways. Close to half of the genetic susceptibility loci associated with polygenic SLE involve type 1 IFN production or downstream signaling [<a href="#rid50">50</a>], and several of these genes are hypomethylated [<a href="#rid51">51</a>]. Overexpression of IFN-alpha-induced genes is found in the peripheral blood and tissues of 60 to 80 percent of patients with SLE [<a href="#rid52">52,53</a>]. This is not specific for SLE. Some of the lupus-predisposing polymorphisms in <em>STAT4</em>, <em>PTPN22</em>, and <em>IRF5</em> are associated with high levels of or increased sensitivity to IFN-alpha [<a href="#rid52">52,54,55</a>]. Most genetic influences are complex and depend on gene polymorphisms and gene expression, which is influenced by epigenetic modification, short-interfering ribonucleic acids (siRNAs), and gene copies. As an example, expression of TLR7 protein depends upon genetic polymorphisms, their interaction with at least one microRNA (miRNA), and the number of gene copies [<a href="#rid56">56,57</a>].</p><p>Still other predisposing genes involve lymphocyte signaling (<em>PTPN22</em>, <em>OX40L</em>, <em>PD-1</em>, <em>BANK-1</em>, <em>LYN</em>, <em>BLK</em>), each of which plays a role in activation or suppression of T- or B-cell activation or survival. Other genes influence clearance of immune complexes (complement components C1q, C4, and C2 mentioned above; FcgammaRIIA; RIIIB; CRP; and integrin alpha M [ITGAM]). In some cases, the genetic component is found in promoter regions (eg, interleukin [IL]-10) or is conferred by a variation in gene copy number rather than by different alleles (eg, FcgammaR3 and complement C4) [<a href="#rid57">57-60</a>]. Some of these genetic markers associated with SLE have differences based on their ancestral (racial) background [<a href="#rid61">61</a>].</p><p>In addition to genome-encoded susceptibility genes, epigenetic modifications are important in the pathogenesis of SLE because they regulate gene transcription (generally hypomethylation increases transcription and hypermethylation decreases it); these include hypomethylation of DNA [<a href="#rid51">51,62</a>], especially in T and B lymphocytes and monocytes. The hypomethylation affects specific genes, as does variation in acetylation of histones. The influence of miRNA, some of which control epigenetic modifications, on transcription of several SLE-predisposing genes has been identified [<a href="#rid62">62-64</a>]. There may be as many as 1850 human transcription factors (TF). These interact with specific DNA-binding elements in the promoters of certain genes to promote transcriptional initiation. Defects in TF regulation play critical roles in the immune system. In SLE, both up-regulatory and downregulatory TFs have been identified [<a href="#rid65">65</a>]. Other abnormalities in SLE patients have also been described, not only in gene transcription but also in post-transcriptional regulation, messenger RNA (mRNA) editing, alternative splicing, and protein modification (such as ubiquitination and folding) [<a href="#rid65">65</a>].</p><p>In understanding the role of genes and their modifications in SLE, it is important to remember that many of the SLE genetic studies have included all patients with SLE together. However, several have studied immunologic and clinical subsets [<a href="#rid66">66-68</a>]. There are known associations between certain gene polymorphisms and nephritis (including genes that modulate the renal disease but do not predispose to SLE per se) [<a href="#rid69">69</a>], as well as genes associated with arthritis, cytopenias, dermatitis, anti-DNA, anti-Ro/La, and anti-Sm. An additional complexity of understanding mechanisms by which genes modulate disease is variability of gene and protein expression depending upon whether the source is whole blood, isolated peripheral blood mononuclear cells, neutrophils, monocyte/macrophages, dendritic cells, or B or T cells (including different subsets of these cell types) [<a href="#rid70">70</a>].</p><p>Stratification by disease phenotypes may be of benefit in genetic analyses of molecular pathogenesis. A GWAS of SLE patients stratified by ancestry and extremes of phenotype in serology and serum IFN-alpha, and using a multi-step screening approach, identified several loci of particular interest; each of these demonstrated a strong association with increased serum IFN-alpha and a particular serologic profile [<a href="#rid71">71</a>]. These included <em>LRRC20</em> and <em>PPM1H</em> (both with anti-La), <em>LPAR1</em> (with anti-Ro and –Sm), <em>ANKS1A</em> (with anti-Ro and anti-double-stranded DNA [anti-dsDNA]), and <em>VSIG2</em> (with anti-RNP, but lacking anti-Sm). Additionally, SNPs in both <em>PTPRM</em> and <em>LRRC20</em> were associated with increased serum IFN-alpha independent of serologic profile. The findings demonstrate heterogeneity in SLE molecular pathogenesis and indicate the potential importance of these variants for sub-phenotypes of SLE, because none of the SNPs were strongly associated with SLE in case-control analysis.</p><p>Some gene polymorphisms have also been associated with clinical subsets such as: anti-dsDNA (<em>HLA-DR3</em>, <em>HLA-DQA1/DQA2</em>, <em>STAT4</em>, <em>UBE2L3</em>, <em>IR5</em>, <em>BANK1</em>, <em>BLK</em>, <em>ITGAM</em>, <em>ELF1</em>, <em>RASGRP3</em>, <em>PHLDB1</em>, <em>TMC2</em>, <em>NAALADL2</em>, and <em>NOTCH4/C6orf10</em>), nephritis (<em>HLASD2/DR3</em>, <em>STAT4</em>, <em>IRF5</em>, <em>IRF7</em>, <em>SLC15A4</em>, <em>IFIH1</em>, <em>TNFAIP3</em>, <em>TNIP1</em>, <em>UBE2L3</em>, <em>TNFSF4</em>, <em>IKZF1</em>, <em>ELF1</em>, <em>BLK</em>, <em>XKR6</em>, <em>ITGAM</em>, <em>FCGR21/3B,PDGFRA/GSX2</em>, <em>SLC5A11</em>, <em>ID4</em>, and <em>HAS2/SNTB1</em>), cutaneous manifestations (<em>IFIH1</em>, <em>IRF5</em>, <em>TNIP1</em>, <em>SLC15A4</em>, <em>TYK2</em>, <em>UBE2L3</em>, <em>RASGRP3</em>, <em>IKZF1</em>, <em>ITGAM</em>, <em>FCGAM</em>, and <em>FCGR2A)</em>, neurologic manifestations (<em>STAT4</em>, <em>TNFAIP3</em>, <em>IL12B</em>, <em>ITGAM</em>, and <em>FCGR3A/3B</em>), arthritis (<em>ITGAM</em>, <em>MIR14GA</em>, and <em>IRF5)</em>, serositis (<em>STAT4</em>, <em>TNIP1</em>, and <em>FCGR2A)</em>, oral ulcers (<em>STAT4</em> and <em>ETS1)</em>, and hematologic manifestations (<em>TNFAIP3</em> and <em>BLK)</em> [<a href="#rid72">72</a>]. Polymorphisms in <em>APOL1</em> predispose to worse kidney disease in all nondiabetic forms of nephritis, including lupus nephritis; the increased frequency of such variants in people with African ancestry may contribute to worse outcomes for these patients [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/d/html/7236.html" rel="external">"Epidemiology of chronic kidney disease", section on 'Apolipoprotein L1 in African Americans'</a>.)</p><p>In summary, except for the rare <em>TREX1</em> mutation or deficiencies of early components of complement, there is no single gene polymorphism that creates high risk for SLE. Thus, some combination of the presence of susceptibility genes, the absence of protective genes (such as <em>TLR5</em> polymorphism or loss-of-function <em>PTPN22</em> variant), and the presence of variants in other genes that influence cell function is required to "achieve" enough genetic susceptibility to permit disease development [<a href="#rid74">74,75</a>]. It is highly likely that additional epigenetic changes and/or environmental triggers are also required [<a href="#rid76">76,77</a>]. While evidence describing the cumulative effect of genetic risk factors is limited, one cohort study of 1655 patients with SLE found that the combined number of genetic risk variants (as calculated by a weighted genetic risk score) was higher among patients with childhood-onset SLE versus those with disease onset in adulthood [<a href="#rid78">78</a>]. A higher weighted genetic risk score was also associated with certain disease manifestations, including types of lupus nephritis.</p><p class="headingAnchor" id="H8"><span class="h2">Hormonal factors</span><span class="headingEndMark"> — </span>The immunoregulatory function of estradiol, testosterone, progesterone, dehydroepiandrosterone (DHEA), and pituitary hormones, including prolactin, has supported the hypothesis that they modulate the incidence and severity of SLE [<a href="#rid14">14,15,79,80</a>]. In support of the potential role of estrogens in predisposing to SLE, the Nurse's Health study showed that women with early menarche, or treated with estrogen-containing regimens such as oral contraceptives or postmenopausal hormone replacement therapies, have a significantly increased risk for SLE (HR of 1.5 to 2.1 ) [<a href="#rid14">14,81</a>]. However, others have either noted no effect of varied hormone levels, or treatment with hormones, on inducing lupus or flares thereof, or equivocal effects [<a href="#rid79">79,81-84</a>]. On the other hand, estrogen can stimulate the type 1 IFN pathway, while progesterone may inhibit it, suggesting that a balance between the two hormones may be important [<a href="#rid85">85</a>].</p><p>The pathogenic role of hormones in SLE may be related to their effects on immune responsiveness. Estrogen stimulates thymocytes, CD8+ and CD4+ T cells, B cells, macrophages, the release of certain cytokines (eg, IL-1), and the expression of both HLA and endothelial cell adhesion molecules (VCAM, ICAM) [<a href="#rid86">86,87</a>]. Estrogen also causes increased macrophage proto-oncogene expression and enhanced adhesion of peripheral mononuclear cells to endothelium [<a href="#rid86">86</a>]. Another potentially important effect of estradiol may be its ability to reduce apoptosis in self-reactive B cells, thus promoting selective maturation of autoreactive B cells with high affinity for anti-DNA [<a href="#rid88">88</a>]. Consequently, women are more predisposed to make autoantibodies that eventually lead to clinically apparent SLE. By comparison, androgens tend to be immunosuppressive [<a href="#rid89">89</a>]. Serum levels of DHEA, an intermediate compound in testosterone synthesis, are low in nearly all patients with SLE. Estrogen upregulates IL-21 expression in CD4+ T cells [<a href="#rid90">90</a>].</p><p>Progesterone and prolactin also affect immune activity [<a href="#rid91">91,92</a>]. Progesterone downregulates T-cell proliferation and increases the number of CD8 cells [<a href="#rid91">91</a>], while lupus flares have been associated with hyperprolactinemia [<a href="#rid93">93</a>]. In addition, both progesterone and high levels of estrogen promote a Th2 response, which favors autoantibody production [<a href="#rid15">15</a>].</p><p>Thyroid hormone may influence SLE, or vice versa. There is an increased incidence of thyroid disease in patients with SLE. In one study of 41 patients with SLE, for example, the incidence of both antithyroid antibodies (51 versus 27 percent) and elevated serum thyroid-stimulating hormone (TSH) levels (24 versus 12 percent) were higher than in controls [<a href="#rid94">94</a>].</p><p>Abnormalities of the hypothalamus-pituitary-adrenal axis may also exist among those with SLE. SLE patients appear to have an abnormal reaction to stress characterized by a heightened response to human corticotropin-releasing hormone (hCRH) [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Immune abnormalities</span><span class="headingEndMark"> — </span>There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary, genetically controlled, or secondarily induced. In certain cases, these immune defects are episodic, and some correlate with disease activity.</p><p>SLE is primarily a disease with abnormalities in immune regulation [<a href="#rid96">96-98</a>]. Anti-dsDNA antibodies are detected in the serum of all healthy individuals [<a href="#rid99">99</a>]. However, clinical assays for anti-dsDNA are calibrated in such a way that arbitrary units differentiate the levels in healthy individuals from patients with "definite" SLE. Thus, patients with SLE tend to make more anti-dsDNA antibodies than healthy individuals and most people with other diseases [<a href="#rid99">99</a>]. These abnormalities are thought to be secondary to a loss of self-tolerance; thus, affected patients (either before or during disease evolution) are no longer totally tolerant to all of their self-antigens and consequently develop an exaggerated autoimmune response [<a href="#rid99">99-101</a>].</p><p>The mediators of SLE are autoantibodies and the immune complexes they form with antigens; the autoantibodies are usually present for years before the first symptom of disease appears [<a href="#rid102">102</a>]. Self-antigens that are recognized are presented primarily on cell surfaces or extracellular protein nets, particularly by cells that are activated or undergoing apoptosis (or NETosis in the case of neutrophils), where intracellular antigens access cell surfaces where they can be recognized by the immune system [<a href="#rid103">103,104</a>].</p><p>Phagocytosis and clearing of immune complexes, of apoptotic cells, and of necrotic cell-derived material are defective in SLE, allowing persistence of antigen and immune complexes [<a href="#rid72">72,104,105</a>]. B cells/plasma cells (PC) that make autoantibodies are more persistently activated and driven to maturation by B-cell activating factor (BAFF, also known as B lymphocyte stimulator, BLyS) and by persistently activated T helper cells making B-supporting cytokines such as IL-6 and IL-10. In tissue, follicular helper T cells (Tfh) and IL-17-producing T cells (Th17) also promote autoantibody formation [<a href="#rid106">106,107</a>]. This induction of higher levels of autoantibodies than in healthy individuals reflects a defect in the mechanisms of self-tolerance [<a href="#rid108">108</a>]. Tfh support high-affinity autoreactive B cells and lymphoid germinal center formation. Th17 are enriched in renal tissue of lupus nephritis; they produce IL-21, which causes tissue damage and helps B cell survival. BAFF (BLyS), serum levels of which are elevated in many patients with SLE, is essential for maturation and survival of post-bone marrow transitional and immature B cells into autoantibody-secreting plasmablasts and memory B cells [<a href="#rid109">109</a>]. Both short- and long-lived PC make anti-DNA; targeting both might be desirable to suppress SLE; short-lived cells are more easily depleted by available approaches, such as by proteasome inhibitors. In untreated SLE, the increased autoantibody production and persistence is not downregulated appropriately by anti-idiotypic antibodies or regulatory immune cells (CD4+CD25hi-Foxp3+ Treg cells, Foxp3+CD8+ Tregs, CD4+T17regs, Bregs, myeloid regulatory cells, and natural killer [NK] cells).</p><p>Some antibody/antigen complexes, particularly those containing DNA or RNA/proteins, activate the innate immune system via <em>TLR9</em> or <em>TLR7</em>, respectively. Thus, dendritic cells are activated and release type 1 IFNs and tumor necrosis factor (TNF)-alpha; T cells release IFN-gamma, IL-6, and IL-10; while NK and T cells fail to release adequate immunosuppressive quantities of transforming growth factor (TGF)-beta. NK cells also appear to be impaired in their regulatory function due to a subtype of NK cells that look like dendritic cells [<a href="#rid110">110</a>].These cytokine patterns favor continued autoantibody formation [<a href="#rid111">111</a>].</p><p>The innate immune system may also be activated by infections (bacterial or RNA- or DNA-containing viruses). Thus, both innate and adaptive immunity conspire to continually produce autoantibodies and to promote inflammation; if regulation of that response fails over time, clinical disease results.</p><p>There has been much interest in alterations in cellular metabolism that control differentiation, proliferation, and function of various immune cells [<a href="#rid112">112</a>]. In normal immunity, lymphocytes (and most eukaryotic cells) use oxidative phosphorylation (OXPHOS) to generate adenosine triphosphate (ATP); this occurs in mitochondria [<a href="#rid113">113</a>]. When cells are activated (effector helper T cells, plasmablast/plasmacytes), they switch to primarily a glycolytic pathway that begins in cell cytoplasm. Glucose (and some amino acids) activate energy through protein kinase pathways that include PI3K/Akt and mechanistic target of rapamycin (mTOR). mTOR, a serine/threonine protein kinase, senses nutrients, energy production, and redox potentials. It then controls additional energy activation/metabolic pathways, cell differentiation, survival, proliferation, autophagy, and protein production. In glycolysis, pyruvate is generated, which on entering mitochondria, activates the tricarboxylic acid (TCA)/Krebs cycle pathway, which generates ATP less efficiently than OXPHOS. Products of glycolysis include reactive oxygen species (ROS) that can damage cells and tissues. If, in contrast, the cells use glutaminolysis, the pentose phosphate (PPP) pathway activates and produces antioxidants; it is anabolic relative to catabolic effects of glycolysis. For example, macrophages of M1 type (pro-inflammatory) use aerobic glycolysis and generate ROS; the M2 type (healing) use the PPP pathway and have antioxidant properties. In contrast to glycolysis in activated T helper cells, the OXPHOS pathway is used by memory T, memory B, and regulatory T cells. Suppressing glycolysis results in higher numbers and function of Tregs. In patients with SLE, CD4+ T cells and CD19+ B cells have dysfunctional mitochondria and elevations in activated mTOR, resulting in depletion of ATP and increases in glycolysis, ROS production, and differentiation of naïve T cells into Th1, Tfh, and Th17 subsets. There is also abnormal cell persistence, autophagy, and cytokine production. Several investigators have suggested (and have in clinical trials) using in SLE patients inhibitors of mTOR such as rapamycin/<a class="drug drug_general" data-topicid="10329" href="/d/drug information/10329.html" rel="external">sirolimus</a>, inhibitors of glycolysis such as 2 deoxy-d-glucose, and inhibitors of mitochondrial transport chains such as <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a> [<a href="#rid114">114</a>].</p><p>The following are some of the immune abnormalities that have been described in SLE that relate to the vicious cycle described in the preceding paragraphs:</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated circulating levels of IFN-alpha and increased expression of IFN-alpha-inducible RNA transcripts by mononuclear cells, especially in patients with active disease, occur in blood and tissues of most SLE patients [<a href="#rid115">115-122</a>]. The elevated levels of IFN-alpha and increased expression of IFN-alpha-inducible transcripts may be due in part to the presence of predisposing genetic factors affecting IFN expression [<a href="#rid123">123</a>]. A similar increase in IFN-alpha-inducible transcripts occurs in synovial tissue [<a href="#rid124">124</a>]. Patients with the SLE risk-enhancing <em>PTPN22</em> <em>C1858T</em> allele are more likely to have elevated circulating INF-alpha, which may contribute to inflammation [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in circulating PC and in an autoreactive subset of memory B cells is associated with disease activity in SLE [<a href="#rid125">125,126</a>]. By contrast, an increase in neutrophil signature was associated with nephritis in one study of patients with pediatric lupus [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A decrease in cytotoxic T cells and in functions of suppressor T cells (which would normally downregulate immune responses) occurs in most patients [<a href="#rid127">127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired generation of polyclonal T-cell cytolytic activity occurs in some [<a href="#rid128">128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increase in circulating and germinal follicular helper (CD4+) T cells and helper function by both CD4+ and CD8+ T cells is characteristic [<a href="#rid129">129-131</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polyclonal activation of B cells and abnormal B-cell receptor signaling [<a href="#rid129">129,132</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple signaling abnormalities of T and B lymphocytes, including cellular hyperactivity and hyperresponsiveness, which may be partially due to genetically or epigenetically determined defects occur in most patients [<a href="#rid107">107,133-135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic abnormalities occur in lupus T and B cells associated with mitochondrial hyperpolarization and dysfunction resulting in prolonged use of glycolytic pathways (decreasing ATP, generating ROS, promoting T cell differentiation into Th1, Tfh, and Th17 that promote B cell autoantibody production, reduction of regulatory T cells and their functions), rather than the more "protective" pathways of OXPHOS and PPP, which generate ATP more efficiently and provide antioxidants, respectively.</p><p></p><p class="bulletIndent1">Dysfunctional signaling in T and B cells, which is manifested by increased calcium responses to antigen stimulation; hyperphosphorylation of cytosolic protein substrates; decreased nuclear factor kB; and abnormal voltage-gated potassium (Kv1.3) channels are implicated in facilitating excessive calcium entry into T cells [<a href="#rid136">136,137</a>]. IgG directed against CD3 (perhaps TCR on CD3+ cells) upregulates expression of CREM to the IL-2 promoter, which reduces IL-2 production; this effect requires CaMKIV [<a href="#rid138">138</a>]. These changes probably account for the decreased IL-2 production of lupus T cells, which might contribute to inability to generate adequate numbers of functioning regulatory T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Defects in B-cell tolerance, perhaps related to defects in apoptosis and/or complement deficiency, lead to prolonged lives of autoreactive B cells [<a href="#rid86">86,139-141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased BAFF (BLyS) expression may promote autoimmunity. B cells have three receptors for BAFF: BAFFR, B-cell maturation antigen (BCMA), and transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) [<a href="#rid109">109,142</a>]. BAFF, which is produced primarily by neutrophils and monocyte/macrophages, increases survival of B2 cells after their transitional T1 phase (which means the B cells have survived several deleting and anergizing tolerance mechanisms), as well as survival of resting memory B cells and plasmablasts. Stimulation by BAFF is particularly important for the survival of T-dependent B cells, the source of many autoantibodies. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>.)</p><p></p><p class="bulletIndent1">Increased BAFF (BLyS) production is promoted by increased TLR activation and increased type 1 and 2 IFNs; in turn, BAFF promotes increased TLR activation. Thus, BAFF can contribute to sustained autoantibody production by several mechanisms. Clinical trials have demonstrated that <a class="drug drug_general" data-topicid="16479" href="/d/drug information/16479.html" rel="external">belimumab</a>, a monoclonal antibody to BAFF, is beneficial for the treatment of patients with SLE, including lupus nephritis, for whom its use has been approved by the US Food and Drug Administration (FDA) [<a href="#rid109">109,142-144</a>]. A proliferation-inducing ligand (APRIL), made primarily by dendritic cells, binds TACI and an additional B-cell receptor, BCMA. In some conditions, APRIL promotes B-cell survival and in others can provide a negative signal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BTK (Bruton's tyrosine kinase), which affects B cell function through the B cell receptor is overexpressed in B cells, which leads to overproduction of ANA and immune complex deposition in glomeruli [<a href="#rid145">145</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased fetal microchimerism occurs during pregnancies in women with SLE [<a href="#rid146">146</a>], providing "foreign" antigens to the immune system.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased levels of microparticles (MPs) are found in SLE. Microparticles are small, membrane-bound vesicles that contain DNA, RNA, nuclear proteins, cell-adhesion molecules, growth factors, and cytokines. These MPs are shed from cells during apoptosis or activation. MPs can drive inflammation and autoimmunity, including through immune complexes [<a href="#rid147">147</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis [<a href="#rid148">148</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with SLE treated with antimalarials, a genotype associated with low TNF and high IL-10 levels correlated with higher serum concentrations of IFN-alpha, while those with high TNF-alpha and low IL-10 levels had increased numbers of regulatory T cells [<a href="#rid148">148</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased numbers of circulating neutrophils that are undergoing NETosis, a form of apoptosis specific for neutrophils; these cells release DNA bound to protein in protein nets, which stimulates anti-DNA and IFN-alpha production [<a href="#rid149">149-151</a>], probably involving <em>TLR9</em>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormally high levels of erythrocyte C4-derived activation fragments (C4d) and low levels of erythrocyte complement receptor (CR1) [<a href="#rid152">152</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal <em>TLR7</em> signaling in response to RNA and <em>TLR9</em> signaling in response to DNA [<a href="#rid153">153,154</a>] and increased expression of <em>TLR9</em> on peripheral blood B cells, PC, and dendritic cells [<a href="#rid153">153,155-159</a>]. This means that B cells can be activated to secrete autoantibody by the innate immune system, independent of T-cell help.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stimulation of <em>TLR7</em> or <em>TLR9</em> reduces the immunosuppressive activity of glucocorticoids, suggesting that nucleic acid containing immune complexes that induce TLR signaling may limit effectiveness of glucocorticoids and may account for the high doses sometimes required for therapy [<a href="#rid160">160</a>]. Correspondingly, blocking stimulation of <em>TLR7</em> or <em>TLR9</em> may be useful therapeutically and restore sensitivity to glucocorticoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher expression of <em>TLR9</em> on B cells as well as low CH50 levels associated with increased SLE Disease Activity Index (SLEDAI) scores [<a href="#rid157">157</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased serum levels of HMGB1 (high mobility group box chromosomal protein 1) in patients with SLE is associated with disease activity [<a href="#rid161">161,162</a>]. Whether this is specific for SLE is as yet not clear; antibodies to HMG have been noted in patients with juvenile idiopathic arthritis [<a href="#rid163">163</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disrupted T effector cell differentiation involving the Wnt/beta-catenin pathway contribute to immune dysfunction in SLE [<a href="#rid164">164</a>].</p><p></p><p>These changes promote the production of antinuclear antibodies (ANAs, see below). In addition, certain strains of mice (eg, those with the lpr, also known as Fas-/FasL- mutation) have a genetic defect in apoptosis, resulting in abnormal programmed cell death that allows the development of autoreactivity and the dramatic increase in an aberrant lymphoid population. Humans with a comparable mutation (ie, autoimmune lymphoproliferative syndrome) display abnormal lymphoproliferation in association with cytopenias and autoimmunity. In humans with lupus, dysregulation of apoptosis has been demonstrated among different cell types, particularly T lymphocytes and the Fas/Fas ligand pathway [<a href="#rid133">133</a>]; some SLE patients also have defective clearing of apoptotic cells [<a href="#rid165">165</a>]. (See  <a class="medical medical_review" href="/d/html/5594.html" rel="external">"Apoptosis and autoimmune disease", section on 'Autoimmune lymphoproliferative syndrome'</a>.)</p><p>C1q and antiphospholipid antibodies enhance opsonization and clearance [<a href="#rid166">166-169</a>]; thus, depressed levels of C1q and C4 may impair phagocytosis and delay clearance [<a href="#rid170">170,171</a>]. The act of phagocytosis results in a stimulation of the immune response to autoantigens derived from the apoptotic cells [<a href="#rid172">172,173</a>]. In addition, protein cleavage by caspases and granzyme B may promote the antigenicity of the contents of apoptotic cells [<a href="#rid104">104</a>].</p><p>Cleavage of complement with production of breakdown products is characteristic of most patients with active SLE. In fact, hypocomplementemia (especially in addition to rising serum levels of anti-DNA) is a fairly good predictor of disease flare. Measurement of C4d (a breakdown product) bound to erythrocytes and/or to B cells has been reported to distinguish SLE from similar diseases and perhaps to be useful in predicting flares [<a href="#rid174">174</a>].</p><p>As noted above, <em>TLR7</em> and <em>TLR9</em> may play a role in promoting autoimmunity. <em>TLR7</em> and <em>TLR9</em> are involved in the IFN-alpha response [<a href="#rid175">175</a>], and immune complexes containing DNA/autoantibody activate dendritic cells through cooperation of <em>CD32</em> and <em>TLR9</em> [<a href="#rid158">158</a>]; similarly, RNA-containing self-antigens can activate dendritic cells through <em>TLR7</em> [<a href="#rid159">159</a>], both by innate immune stimulation via <em>TLR7</em> (recognizes RNA) and <em>TLR9</em> (recognizes DNA), which can directly stimulate B cells to make autoantibodies, and by T-cell stimulation of B cells via adaptive immunity as well as activating the INF-alpha response (see below) [<a href="#rid151">151</a>]. Antimalarial drugs (eg, <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">hydroxychloroquine</a>) used to treat some manifestations of SLE block <em>TLR7</em> and <em>TLR9</em> signaling.</p><p>These multiple defects cause a cascade of events that begins with abnormal cellular breakdown and ends with the production of autoantibodies. As cells break down abnormally, certain (especially nuclear and cryptic self peptides [<a href="#rid176">176</a>]) antigens are processed (perhaps abnormally [<a href="#rid177">177,178</a>]) into peptides by antigen-presenting cells such as macrophages, B lymphocytes, and dendritic cells [<a href="#rid100">100,179</a>]. Alternatively, microorganisms may be broken down within antigen-presenting cells into "mimicry peptides" that have sufficient structural similarity with immunodominant self peptides [<a href="#rid180">180</a>]. It is likely that the microbiome of many organs provides additional antigens to stimulate antibody formation. A study in SLE patients compared with healthy controls showed in the intestinal microbiota a fivefold increase in <em>Ruminococcus gnavus </em>(RG) of the <em>Lachnospiraceae</em> family, whereas other taxonomic microbial groups were decreased. In addition, the increase correlated with high SLE disease activity; antibodies to cell wall lipoglycans from RG correlated with active nephritis, high disease activity, high anti-dsDNA, and low C3 and C4 levels [<a href="#rid181">181</a>].</p><p>With any of these mechanisms, a peptide-MHC complex forms and stimulates the activation and clonal expansion of CD4+ autoreactive T cells [<a href="#rid180">180</a>]. These cells, via contact plus release of cytokines (eg, IL-4, IL-6, and IL-10) [<a href="#rid100">100,182</a>], cause autoreactive B cells to become activated, proliferate, and differentiate into antibody-producing cells that make an excess of antibodies to many nuclear antigens [<a href="#rid100">100,179</a>]. At the same time, activation of the innate immune system with release of IL-1, TNF-alpha, type 1 IFNs, BAFF (BLyS), and APRIL promotes inflammation and survival of autoreactive B cells. Thus, a specific immune profile develops that is characterized by the development of elevated levels of ANAs, especially to DNA, Sm, RNP, Ro, La, nucleosomes, and other nuclear antigens [<a href="#rid100">100,183-185</a>]. Several of these autoantibodies are important clinically. ANAs appear at some time during the course of disease in &gt;95 percent of patients with SLE, so its absence on multiple testings suggests SLE is not the correct diagnosis. Anti-dsDNA is associated with higher risks for nephritis; anticardiolipins are associated with higher risk for clotting and fetal loss. Anti-Ro/SSA is associated with a chronic form of lupus dermatitis as well as with higher risk for neonatal lupus in babies of mothers with SLE.</p><p>ANAs are made to antigens from active sites on molecules involved in essential cellular functions (such as RNA splicing) [<a href="#rid185">185</a>]. With continued pressure over time from self-antigens, the immune response switches, via somatic hypermutation, from low-affinity, highly cross-reactive immunoglobulin M (IgM) antibodies; to high-affinity IgG antibodies; and then finally to antibodies directed toward more limited epitopes on self-antigens [<a href="#rid186">186</a>]. Idiotypes of antibodies may then stimulate autoreactive T cells to expand, thereby helping unique clones of B cells to expand [<a href="#rid187">187</a>]. The final result is the production of more specific ANAs [<a href="#rid188">188</a>], which may precede clinical manifestations by years [<a href="#rid102">102,151,189</a>].</p><p>Not all autoantibodies cause disease. In fact, all normal individuals make autoantibodies, although in small quantities. The variability in clinical disease that exists among different patients may therefore reflect the variability in the quality and quantity of the immune response, including regulatory networks.</p><p class="headingAnchor" id="H10"><span class="h2">Environmental factors</span><span class="headingEndMark"> — </span>The environment probably has a role in the etiology of SLE via its effects on the immune system.</p><p class="bulletIndent1"><span class="glyph">●</span>Viruses, for example, may stimulate antigen-specific cells in the immune network [<a href="#rid100">100,190,191</a>]. In addition, trypanosomiasis or mycobacterial or Epstein-Barr virus (EBV) infections may induce anti-DNA antibodies or even lupus-like symptoms, and lupus flares may follow bacterial infections (perhaps related to bacterial CpG motifs) [<a href="#rid136">136,192</a>]. Patients with SLE also have higher titers of antibodies to EBV, have increased circulating EBV viral loads, and make antibodies to retroviruses, including to protein regions homologous to nuclear antigens [<a href="#rid193">193,194</a>]. In fact, studies in children with SLE suggest that EBV infection may be a triggering event resulting in clinical SLE [<a href="#rid193">193</a>]. Antibodies to these molecular mimicry molecules, and to endogenous retroviruses, may contribute to the development of autoimmunity [<a href="#rid195">195,196</a>]. The balance of the microbiome of various organs probably contributes to autoimmunity [<a href="#rid181">181</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is limited evidence to suggest that bacterial infections may trigger increased immune activation and inflammation, thereby playing a role in potentially stimulating activation of autoreactive lymphocytes resulting in worsening lupus symptoms [<a href="#rid197">197</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultraviolet (UV) light may stimulate keratinocytes to express more snRNPs on their cell surface [<a href="#rid198">198,199</a>] and to secrete more IL-1, IL-3, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), and TNF-alpha, thereby stimulating B cells to make more antibodies. In addition to the local effects in skin, UV light may also increase the degree of systemic autoimmunity by interfering with antigen processing by and activation of macrophages. UV light decreases T-cell DNA methylation, which may lead to overexpression of lymphocyte function-associated antigen (LFA)-1 [<a href="#rid200">200</a>]. These T cells may then become autoreactive, resulting in autoantibody formation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Silica dust, found in cleaning powders, soil, pottery materials, cement, and cigarette smoke, may increase the risk of developing SLE, especially in African American women [<a href="#rid13">13,201-206</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Allergies to medications, particularly to antibiotics, are reported more frequently in patients with newly diagnosed SLE than healthy controls [<a href="#rid191">191</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a slight, but significantly higher prevalence of lupus in pet dogs of patients with SLE (three cases among 59 pet dogs owned by 37 SLE patients, versus none among 187 dogs in non-SLE households) [<a href="#rid207">207</a>]. These observations suggest a possible common environmental factor for both human and dog systemic lupus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no apparent association between SLE and the use of hair dyes, lipstick, occupational solvent exposure, the use of pesticides, or alcohol consumption [<a href="#rid203">203,208</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Past and present cigarette smoking appears to be a risk factor for the development of SLE [<a href="#rid209">209</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h1">PATHOGENESIS OF CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Although the exact etiology of systemic lupus erythematosus (SLE) remains obscure, it is clear that many of the clinical manifestations of SLE are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). As an example, IC deposition and subsequent complement activation in the kidney is responsible for much of the tissue damage of lupus nephritis (see  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>). IC have also been detected (by immunofluorescence and/or electron microscopy) at the dermal-epidermal junction in both skin lesions and normal skin, as well as in the choroid plexus, the pericardium, and the pleural cavity.</p><p>The pathogenic potential of IC varies, depending on the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The characteristics of the antibody, such as its specificity, affinity, charge, and ability to activate complement or other mediators of inflammation. In the glomerulus, for example, different antibodies may bind to antigens at different sites in the glomerular capillary wall, leading to different histologic and clinical manifestations [<a href="#rid210">210,211</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The nature of the antigen, such as its size and charge. Smaller cationic antigens, for example, are more able to cross the glomerular basement membrane and be deposited in the subepithelial region. The ensuing formation of IC should lead to membranous nephropathy rather than a proliferative glomerulonephritis. (See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Pathogenesis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ability of the IC to be solubilized by complement and bound to the complement receptor (CR1) on red blood cells (both systems may be defective in SLE).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rate at which the IC are cleared by immunoglobulin Fc receptors on monocytes/macrophages in the liver and spleen from the circulation may be genetically impaired in SLE [<a href="#rid212">212</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Initiation of kidney disease in SLE is likely due to the deposition or formation of immune complexes in the mesangium, subendothelial, or subepithelial spaces, with subsequent activation of complement.</p><p>IC in this disease consist of nuclear antigens (especially DNA), and high-affinity, complement-fixing immunoglobulin G (IgG) antinuclear antibodies (ANAs) [<a href="#rid213">213</a>] (especially IgG1 and IgG3 [<a href="#rid214">214</a>]), and antibodies to DNA [<a href="#rid215">215</a>]. These complexes either form in the circulation, where they are poorly cleared [<a href="#rid216">216</a>] or form in situ as free antibody binds to free antigen that has already deposited in the glomerulus or is an intrinsic glomerular antigen [<a href="#rid217">217</a>]. Histones have high affinity for the glomerular basement membrane (GBM) and may facilitate IC deposition [<a href="#rid218">218</a>]. Antibody reactivities in the serum that best correlate with active nephritis in human SLE are directed against DNA/chromatin or laminin/myosin/vimentin/heparan sulfate [<a href="#rid219">219</a>], suggesting the importance of these reactivities to pathogenesis.</p><p>Elevated levels of anti-DNA antibodies commonly precede development of clinical lupus nephritis. This was illustrated in a study of serum samples collected from military recruits. Among those who developed SLE and renal disease, 92 percent had elevated levels of anti-double-stranded DNA (anti-dsDNA) antibodies present before diagnosis [<a href="#rid189">189</a>]. In addition, the combination of a rising level (titer) of anti-DNA and evidence of increased complement activation (eg, rising C3a), if detected, may allow preemptive treatment and avoid lupus flares [<a href="#rid220">220</a>].</p><p>Once deposited in the mesangial or subendothelial aspect of the GBM, IC activate the complement system, thereby generating chemotactic factors that attract the infiltration of leukocytes and mononuclear cells. These cells phagocytose IC and release mediators (such as cytokines and activators of the clotting system) that perpetuate glomerular inflammation. With continuing IC deposition, chronic inflammation may ensue, ultimately leading to fibrinoid necrosis, scarring, and reduced renal function.</p><p>In addition, in situ antibody deposition occurring in the subepithelial space in lupus membranous nephropathy is not associated with cell damage. In this setting, complement is activated at a site that is separated from circulating inflammatory cells by the GBM [<a href="#rid221">221</a>]. As a result, these patients develop epithelial cell injury and proteinuria but not active inflammation and proliferative glomerulonephritis.</p><p>An important consideration for likelihood of developing chronic renal disease, or end-stage kidney disease, is the influence of immune deposition and complement activation on non-immune cells in the target tissue. When lupus nephritis begins, there is activation of endothelial cells, mesangial cells, podocytes, renal tubular epithelial cells, and tissue-fixed macrophages. It is possible that injury to any of these cells, or their combinations, activates pathways that can lead to glomerulosclerosis, interstitial nephritis, and interstitial fibrosis even if the initial offending immune attack subsides.</p><p class="headingAnchor" id="H13"><span class="h2">Cell-surface antibodies</span><span class="headingEndMark"> — </span>SLE patients make antibodies to a number of cell-surface antigens. Antibodies to a 66-kDa membrane antigen have been implicated in lupus nephritis, vasculitis, and hypocomplementemia, as well as antibodies to a 55-kDa antigen and to an 18-kDa protein in thrombocytopenia [<a href="#rid222">222</a>], and antibodies to neuronal cells in organic brain disease (see  <a class="medical medical_review" href="/d/html/4863.html" rel="external">"Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Attribution of a clinical syndrome to SLE'</a>). Cell-surface antibodies also attach to red blood cells, lymphocytes, and platelets (see  <a class="medical medical_review" href="/d/html/4670.html" rel="external">"Hematologic manifestations of systemic lupus erythematosus"</a>). In addition, ANAs may interact with nuclear antigens expressed on cell surfaces, triggering cell injury and even death, either by activating complement and/or by cell penetration [<a href="#rid223">223</a>].</p><p>These complexes are cleared from the circulation, and may cause organ damage, through one of the following mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Fc receptors on macrophages of the reticuloendothelial system</p><p class="bulletIndent1"><span class="glyph">●</span>Complement-mediated cytotoxicity</p><p class="bulletIndent1"><span class="glyph">●</span>Antibody-dependent cellular cytotoxicity (ADCC) resulting in hemolytic anemia, leukopenia, and thrombocytopenia</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Antiphospholipid antibodies</span><span class="headingEndMark"> — </span>Patients with SLE may form antibodies to a phospholipid-beta-2-glycoprotein I complex. Beta-2-glycoprotein I normally has an anticoagulant effect that is diminished by blocking effects of the antibody. This may explain why antiphospholipid antibodies are implicated in the etiology of the arterial and venous thromboses (causing strokes and thrombophlebitis), and in placental infarcts (causing miscarriages). Most antibodies that bind cardiolipin also bind beta-2-glycoprotein I; lupus anticoagulants are more likely to bind proteins required for thrombosis or clot lysis, such as thrombin. (See  <a class="medical medical_review" href="/d/html/4676.html" rel="external">"Pathogenesis of antiphospholipid syndrome"</a>.)</p><p>Antiphospholipid antibodies, like ANAs, may be present prior to the diagnosis of SLE. This was illustrated in a study of a cohort of 130 patients for whom stored serum samples that preceded the SLE diagnosis were available [<a href="#rid224">224</a>]. The presence of anticardiolipin antibodies (ACA) was noted in 24 patients who later developed SLE. ACA were detected an average of three years prior to the diagnosis of SLE. In addition, the patients with anticardiolipin antibodies tended to develop more severe lupus than those without these antiphospholipid antibodies. Eleven patients with anticardiolipin antibodies developed thrombotic events prior to the diagnosis of SLE.</p><p class="headingAnchor" id="H15"><span class="h2">Skin lesions</span><span class="headingEndMark"> — </span>Skin lesions are thought to be multifactorial in origin [<a href="#rid225">225</a>] (see  <a class="medical medical_review" href="/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>). In particular, exposure to ultraviolet (UV) light has a number of local effects in the skin:</p><p class="bulletIndent1"><span class="glyph">●</span>It damages DNA. The patient can then make antibodies to DNA, IC form, complement is activated, and a local inflammatory response ensues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It increases binding of anti-Ro, anti-La, and anti-RNP antibodies to UV-activated keratinocytes, which express those antigens in apoptotic blebs on the cell surface [<a href="#rid226">226</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It alters cellular membrane phospholipid metabolism. Portions of cell membranes may be rearranged so the usually cytoplasmic-facing surfaces (and potentially antigenic molecules) flip onto the extracellular surface.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It increases interleukin (IL)-1 release from cutaneous keratinocytes and Langerhans cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It increases apoptosis of keratinocytes in patients with SLE and in healthy persons, but clearance of apoptotic cells by phagocytes is abnormal [<a href="#rid227">227</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It induces inducible nitrogen oxide synthase (iNOS) expression and increased nitric oxide production in keratinocytes [<a href="#rid228">228</a>].</p><p></p><p class="headingAnchor" id="H16"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/581.html" rel="external">"Patient education: Systemic lupus erythematosus (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H443498"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The prevalence of systemic lupus erythematosus (SLE) in the United States is 20 to 150 cases per 100,000. The estimated incidence is 1 to 25 per 100,000 in North America, South America, Europe, and Asia. Both geography and race affect the prevalence of SLE and the frequency and severity of clinical and laboratory manifestations. The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Sex'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age at onset</strong> – Disease onset is between the ages of 16 and 55 in 65 percent of patients, but disease also occurs in both children and older individuals. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factors affecting disease outcome</strong> – Different epidemiologic subgroups, including those based upon race/ethnicity, sex, and age of onset, tend to have varying degrees of disease activity and may differ in their prevalence of given clinical manifestations, which may affect disease outcome. (See <a class="local">'Age at onset'</a> above and <a class="local">'Factors affecting disease outcome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – The etiology of SLE remains unknown and is clearly multifactorial. Many observations suggest a role for genetic, hormonal, immunologic, and environmental factors. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic factors</strong> – There is no single gene polymorphism that creates high risk for SLE, except for the rare <em>TREX1</em> mutation or deficiencies of early components of complement. A combination of factors is likely required to achieve sufficient genetic susceptibility to permit disease development, which may include the presence of susceptibility genes, the absence of protective genes, and the presence of other genes that permit tissue injury after any type of insult. Additionally, some of the single-nucleotide polymorphisms (SNPs) in SLE risk genes predispose to particular clinical subsets of SLE. (See <a class="local">'Etiology'</a> above and <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal factors</strong> – Substantial evidence of the immunoregulatory function of estradiol, testosterone, progesterone, dehydroepiandrosterone (DHEA), and pituitary hormones, including prolactin, has supported the hypothesis that these hormones modulate the incidence and severity of SLE. (See <a class="local">'Hormonal factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune abnormalities</strong> – There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary and which are secondarily induced. In certain cases, these immune defects are episodic, and some correlate with disease activity. (See <a class="local">'Immune abnormalities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Environmental factors</strong> – The environment probably has a role in the etiology of SLE via its effects on epigenetic changes and the immune system. (See <a class="local">'Environmental factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of clinical manifestations</strong> – It is clear that many of the clinical manifestations are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). Initiation of renal disease in SLE is likely due to the deposition or formation of IC in the mesangium, subendothelial, or subepithelial spaces, with subsequent activation of complement. Activated fixed tissue macrophages in the kidney also play a major role in tissue damage. SLE patients make antibodies to a number of cell-surface antigens, such as those to a phospholipid-beta-2 glycoprotein I complex; these antibodies are involved in thromboembolic events and obstetric complications. Skin lesions are thought to be multifactorial in origin; ultraviolet (UV) light has local effects in skin and may increase the degree of autoimmunity. (See <a class="local">'Pathogenesis of clinical manifestations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56:2092.</a></li><li><a class="nounderline abstract_t">Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39:257.</a></li><li><a class="nounderline abstract_t">Izmirly PM, Parton H, Wang L, et al. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol 2021; 73:991.</a></li><li><a class="nounderline abstract_t">Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol 2018; 30:144.</a></li><li><a class="nounderline abstract_t">Tian J, Zhang D, Yao X, et al. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis 2023; 82:351.</a></li><li><a class="nounderline abstract_t">Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42:46.</a></li><li><a class="nounderline abstract_t">Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15:308.</a></li><li class="breakAll">Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus, Wallace DJ, Hahn BH (Eds), Lippincott Williams and Wilkins, Philadelphia 2002.</li><li><a class="nounderline abstract_t">Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28:368.</a></li><li><a class="nounderline abstract_t">Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:847.</a></li><li><a class="nounderline abstract_t">Symmons DP. Frequency of lupus in people of African origin. Lupus 1995; 4:176.</a></li><li><a class="nounderline abstract_t">Chung SA, Tian C, Taylor KE, et al. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis Rheum 2009; 60:2448.</a></li><li><a class="nounderline abstract_t">Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41:1714.</a></li><li><a class="nounderline abstract_t">Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007; 56:1251.</a></li><li><a class="nounderline abstract_t">Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11:352.</a></li><li><a class="nounderline abstract_t">Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013; 72 Suppl 2:ii56.</a></li><li><a class="nounderline abstract_t">Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 2008; 58:2511.</a></li><li><a class="nounderline abstract_t">Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006; 176:7143.</a></li><li><a class="nounderline abstract_t">Lockshin MD. Sex differences in autoimmune disease. Lupus 2006; 15:753.</a></li><li><a class="nounderline abstract_t">Hewagama A, Gorelik G, Patel D, et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun 2013; 41:60.</a></li><li><a class="nounderline abstract_t">Gilbert EL, Ryan MJ. Estrogen in cardiovascular disease during systemic lupus erythematosus. Clin Ther 2014; 36:1901.</a></li><li class="breakAll">Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.</li><li><a class="nounderline abstract_t">Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.</a></li><li><a class="nounderline abstract_t">Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25:55.</a></li><li><a class="nounderline abstract_t">Fernández M, Alarcón GS, Calvo-Alén J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57:576.</a></li><li><a class="nounderline abstract_t">Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 1990; 150:849.</a></li><li><a class="nounderline abstract_t">Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33:37.</a></li><li><a class="nounderline abstract_t">Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990; 33:407.</a></li><li><a class="nounderline abstract_t">Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991; 91:345.</a></li><li><a class="nounderline abstract_t">Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". Medicine (Baltimore) 2004; 83:1.</a></li><li><a class="nounderline abstract_t">Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993; 2:351.</a></li><li><a class="nounderline abstract_t">Johnson AE, Cavalcanti FS, Gordon C, et al. Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus 1994; 3:501.</a></li><li><a class="nounderline abstract_t">Lu LJ, Wallace DJ, Ishimori ML, et al. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119.</a></li><li><a class="nounderline abstract_t">Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.</a></li><li><a class="nounderline abstract_t">Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD. Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 1989; 18:189.</a></li><li><a class="nounderline abstract_t">Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine (Baltimore) 1983; 62:327.</a></li><li><a class="nounderline abstract_t">Ward MM, Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol 1990; 17:220.</a></li><li><a class="nounderline abstract_t">Prete PE, Majlessi A, Gilman S, Hamideh F. Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population. J Clin Rheumatol 2001; 7:142.</a></li><li><a class="nounderline abstract_t">Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989; 32:1226.</a></li><li><a class="nounderline abstract_t">Boddaert J, Huong DL, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004; 83:348.</a></li><li><a class="nounderline abstract_t">Lalani S, Pope J, de Leon F, et al. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol 2010; 37:38.</a></li><li><a class="nounderline abstract_t">Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900.</a></li><li><a class="nounderline abstract_t">Graham RR, Hom G, Ortmann W, Behrens TW. Review of recent genome-wide association scans in lupus. J Intern Med 2009; 265:680.</a></li><li><a class="nounderline abstract_t">Nath SK, Han S, Kim-Howard X, et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; 40:152.</a></li><li><a class="nounderline abstract_t">Boackle SA. Advances in lupus genetics. Curr Opin Rheumatol 2013; 25:561.</a></li><li><a class="nounderline abstract_t">Günther C, Meurer M, Stein A, et al. Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology 2009; 219:162.</a></li><li><a class="nounderline abstract_t">Barcellos LF, May SL, Ramsay PP, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009; 5:e1000696.</a></li><li><a class="nounderline abstract_t">International MHC and Autoimmunity Genetics Network, Rioux JD, Goyette P, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009; 106:18680.</a></li><li><a class="nounderline abstract_t">Bronson PG, Chaivorapol C, Ortmann W, et al. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012; 24:530.</a></li><li><a class="nounderline abstract_t">Yeung KS, Chung BH, Choufani S, et al. Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. PLoS One 2017; 12:e0169553.</a></li><li><a class="nounderline abstract_t">Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182:34.</a></li><li><a class="nounderline abstract_t">Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016; 165:551.</a></li><li><a class="nounderline abstract_t">Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58:2481.</a></li><li><a class="nounderline abstract_t">Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008; 58:2818.</a></li><li><a class="nounderline abstract_t">Deng Y, Zhao J, Sakurai D, et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet 2013; 9:e1003336.</a></li><li><a class="nounderline abstract_t">Berghöfer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088.</a></li><li><a class="nounderline abstract_t">Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68:1746.</a></li><li><a class="nounderline abstract_t">Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.</a></li><li><a class="nounderline abstract_t">Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80:1037.</a></li><li><a class="nounderline abstract_t">Goulielmos GN, Zervou MI, Vazgiourakis VM, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene 2018; 668:59.</a></li><li><a class="nounderline abstract_t">Patel DR, Richardson BC. Dissecting complex epigenetic alterations in human lupus. Arthritis Res Ther 2013; 15:201.</a></li><li><a class="nounderline abstract_t">Shen N, Liang D, Tang Y, et al. MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol 2012; 8:701.</a></li><li class="breakAll">Shen N, Tang Y, Chin Y, et al. Epigenetics of lupus. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace D, Hahn B (Eds), Elsevier, 2018. p.69.</li><li><a class="nounderline abstract_t">Sui W, Hou X, Che W, et al. The applied basic research of systemic lupus erythematosus based on the biological omics. Genes Immun 2013; 14:133.</a></li><li><a class="nounderline abstract_t">Sanchez E, Nadig A, Richardson BC, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1752.</a></li><li><a class="nounderline abstract_t">Taylor KE, Chung SA, Graham RR, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 2011; 7:e1001311.</a></li><li><a class="nounderline abstract_t">Ceccarelli F, Perricone C, Borgiani P, et al. Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J Immunol Res 2015; 2015:745647.</a></li><li><a class="nounderline abstract_t">Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol 2016.</a></li><li><a class="nounderline abstract_t">Grammer AC, Ryals MM, Heuer SE, et al. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis. Lupus 2016; 25:1150.</a></li><li><a class="nounderline abstract_t">Kariuki SN, Ghodke-Puranik Y, Dorschner JM, et al. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun 2015; 16:15.</a></li><li class="breakAll">Deng Y, Tsao BP. Genetics of human SLE. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace D, Hahn B (Eds), Elsevier, 2018. p.54.</li><li><a class="nounderline abstract_t">Friedman DJ, Pollak MR. APOL1 and Kidney Disease: From Genetics to Biology. Annu Rev Physiol 2020; 82:323.</a></li><li><a class="nounderline abstract_t">Hawn TR, Wu H, Grossman JM, et al. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005; 102:10593.</a></li><li><a class="nounderline abstract_t">Orrú V, Tsai SJ, Rueda B, et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009; 18:569.</a></li><li><a class="nounderline abstract_t">Costenbader KH, Gay S, Alarcón-Riquelme ME, et al. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012; 11:604.</a></li><li><a class="nounderline abstract_t">Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25:569.</a></li><li><a class="nounderline abstract_t">Kwon YC, Ha E, Kwon HH, et al. Higher Genetic Risk Loads Confer More Diverse Manifestations and Higher Risk of Lupus Nephritis in Systemic Lupus Erythematosus. Arthritis Rheumatol 2023; 75:1566.</a></li><li><a class="nounderline abstract_t">McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum 2003; 48:2100.</a></li><li><a class="nounderline abstract_t">Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum 2005; 52:3701.</a></li><li><a class="nounderline abstract_t">Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953.</a></li><li><a class="nounderline abstract_t">Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550.</a></li><li><a class="nounderline abstract_t">Sánchez-Guerrero J, Uribe AG, Jiménez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539.</a></li><li><a class="nounderline abstract_t">Sánchez-Guerrero J, González-Pérez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56:3070.</a></li><li><a class="nounderline abstract_t">Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol 2014; 10:740.</a></li><li><a class="nounderline abstract_t">Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol 1995; 13:217.</a></li><li><a class="nounderline abstract_t">Cohen-Solal JF, Jeganathan V, Hill L, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008; 17:528.</a></li><li><a class="nounderline abstract_t">Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006; 305:67.</a></li><li><a class="nounderline abstract_t">Lahita RG. Sex hormones and the immune system--Part 1. Human data. Baillieres Clin Rheumatol 1990; 4:1.</a></li><li><a class="nounderline abstract_t">Lee J, Shin EK, Lee SY, et al. Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology 2014; 142:573.</a></li><li><a class="nounderline abstract_t">Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122:1978.</a></li><li><a class="nounderline abstract_t">Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26:118.</a></li><li><a class="nounderline abstract_t">Blanco-Favela F, Quintal-Alvarez G, Leaños-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26:55.</a></li><li><a class="nounderline abstract_t">Weetman AP, Walport MJ. The association of autoimmune thyroiditis with systemic lupus erythematosus. Br J Rheumatol 1987; 26:359.</a></li><li><a class="nounderline abstract_t">Glück T, Oertel M, Reber T, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis. J Rheumatol 2000; 27:903.</a></li><li><a class="nounderline abstract_t">Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303.</a></li><li><a class="nounderline abstract_t">Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995; 16:90.</a></li><li><a class="nounderline abstract_t">Hahn BH, Ebling F, Singh RR, et al. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 2005; 1051:433.</a></li><li><a class="nounderline abstract_t">Schur PH. Laboratory testing for the diagnosis, evaluation, and management of systemic lupus erythematosus: Still more questions for the next generations: A Tribute and Thanks and in Memory of my mentor: Henry G. Kunkel. Clin Immunol 2016; 172:117.</a></li><li><a class="nounderline abstract_t">Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384.</a></li><li><a class="nounderline abstract_t">Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929.</a></li><li><a class="nounderline abstract_t">Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.</a></li><li><a class="nounderline abstract_t">Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415.</a></li><li><a class="nounderline abstract_t">Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:513.</a></li><li><a class="nounderline abstract_t">Muñoz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1733.</a></li><li><a class="nounderline abstract_t">Kim SJ, Lee K, Diamond B. Follicular Helper T Cells in Systemic Lupus Erythematosus. Front Immunol 2018; 9:1793.</a></li><li><a class="nounderline abstract_t">Katsuyama T, Tsokos GC, Moulton VR. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Front Immunol 2018; 9:1088.</a></li><li class="breakAll">Atisha-Fregoso Y, Zou Y, Diamond B. B cells and generation of antibodies. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace D, Hahn B (Eds), Elsevier, 2018. p.101.</li><li><a class="nounderline abstract_t">Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368:1528.</a></li><li><a class="nounderline abstract_t">Cruz-González DJ, Gómez-Martin D, Layseca-Espinosa E, et al. Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2018; 191:288.</a></li><li><a class="nounderline abstract_t">Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010; 69:1370.</a></li><li><a class="nounderline abstract_t">Teng X, Li W, Cornaby C, Morel L. Immune cell metabolism in autoimmunity. Clin Exp Immunol 2019; 197:181.</a></li><li><a class="nounderline abstract_t">Romo-Tena J, Kaplan MJ. Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update. Curr Opin Rheumatol 2020; 32:562.</a></li><li><a class="nounderline abstract_t">Huang N, Perl A. Metabolism as a Target for Modulation in Autoimmune Diseases. Trends Immunol 2018; 39:562.</a></li><li><a class="nounderline abstract_t">Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408.</a></li><li><a class="nounderline abstract_t">Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711.</a></li><li><a class="nounderline abstract_t">Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3958.</a></li><li><a class="nounderline abstract_t">Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100:2610.</a></li><li><a class="nounderline abstract_t">Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951.</a></li><li><a class="nounderline abstract_t">Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010; 19:1012.</a></li><li><a class="nounderline abstract_t">Jensen MA, Niewold TB. Interferon regulatory factors: critical mediators of human lupus. Transl Res 2015; 165:283.</a></li><li><a class="nounderline abstract_t">Delfani P, Sturfelt G, Gullstrand B, et al. Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity. Lupus 2017; 26:373.</a></li><li><a class="nounderline abstract_t">Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38:550.</a></li><li><a class="nounderline abstract_t">Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56:1579.</a></li><li><a class="nounderline abstract_t">Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:1332.</a></li><li><a class="nounderline abstract_t">Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58:1762.</a></li><li><a class="nounderline abstract_t">Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579.</a></li><li><a class="nounderline abstract_t">Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum 1995; 38:506.</a></li><li><a class="nounderline abstract_t">Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110.</a></li><li><a class="nounderline abstract_t">Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33:1216.</a></li><li><a class="nounderline abstract_t">Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 2012; 39:1819.</a></li><li><a class="nounderline abstract_t">Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:451.</a></li><li><a class="nounderline abstract_t">Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12:523.</a></li><li><a class="nounderline abstract_t">Peng SL. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009; 8:179.</a></li><li><a class="nounderline abstract_t">Wu XN, Ye YX, Niu JW, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med 2014; 6:246ra99.</a></li><li><a class="nounderline abstract_t">Steinberg AD. Insights into the basis of systemic lupus. J Autoimmun 1995; 8:771.</a></li><li><a class="nounderline abstract_t">Tsokos GC. Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. Arthritis Rheum 2008; 58:1216.</a></li><li><a class="nounderline abstract_t">Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115:996.</a></li><li><a class="nounderline abstract_t">Mohan C, Datta SK. Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995; 77:209.</a></li><li><a class="nounderline abstract_t">Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9:721.</a></li><li><a class="nounderline abstract_t">Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703.</a></li><li><a class="nounderline abstract_t">Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008; 223:156.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168.</a></li><li><a class="nounderline abstract_t">Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.</a></li><li><a class="nounderline abstract_t">Kil LP, de Bruijn MJ, van Nimwegen M, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 2012; 119:3744.</a></li><li><a class="nounderline abstract_t">Abbud Filho M, Pavarino-Bertelli EC, Alvarenga MP, et al. Systemic lupus erythematosus and microchimerism in autoimmunity. Transplant Proc 2002; 34:2951.</a></li><li><a class="nounderline abstract_t">Dye JR, Ullal AJ, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol 2013; 78:140.</a></li><li><a class="nounderline abstract_t">López P, Gómez J, Prado C, et al. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008; 35:1559.</a></li><li><a class="nounderline abstract_t">Magna M, Pisetsky DS. The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link? Scand J Immunol 2015; 82:218.</a></li><li><a class="nounderline abstract_t">Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol 2016; 99:265.</a></li><li><a class="nounderline abstract_t">Gensous N, Boizard-Moracchini A, Lazaro E, et al. Update on the cellular pathogenesis of lupus. Curr Opin Rheumatol 2021; 33:190.</a></li><li><a class="nounderline abstract_t">Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3596.</a></li><li><a class="nounderline abstract_t">Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20:538.</a></li><li><a class="nounderline abstract_t">Goodnow CC. Immunology. Discriminating microbe from self suffers a double toll. Science 2006; 312:1606.</a></li><li><a class="nounderline abstract_t">Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54:3601.</a></li><li><a class="nounderline abstract_t">Migita K, Miyashita T, Maeda Y, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34:493.</a></li><li><a class="nounderline abstract_t">Nakano S, Morimoto S, Suzuki J, et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47:145.</a></li><li><a class="nounderline abstract_t">Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407.</a></li><li><a class="nounderline abstract_t">Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19:11.</a></li><li><a class="nounderline abstract_t">Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937.</a></li><li><a class="nounderline abstract_t">Li J, Xie H, Wen T, et al. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37:766.</a></li><li><a class="nounderline abstract_t">Pisetsky DS. The complex role of DNA, histones and HMGB1 in the pathogenesis of SLE. Autoimmunity 2014; 47:487.</a></li><li><a class="nounderline abstract_t">Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J Rheumatol 2010; 37:689.</a></li><li><a class="nounderline abstract_t">Olferiev M, Jacek E, Kirou KA, Crow MK. Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. Clin Immunol 2016; 172:34.</a></li><li><a class="nounderline abstract_t">Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006; 65:216.</a></li><li><a class="nounderline abstract_t">Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41:205.</a></li><li><a class="nounderline abstract_t">Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41:215.</a></li><li><a class="nounderline abstract_t">Charles PJ. Defective waste disposal: does it induce autoantibodies in SLE? Ann Rheum Dis 2003; 62:1.</a></li><li><a class="nounderline abstract_t">Mevorach D. Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis 2010; 15:1114.</a></li><li><a class="nounderline abstract_t">Bijl M, Reefman E, Horst G, et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006; 65:57.</a></li><li><a class="nounderline abstract_t">Munoz LE, Gaipl US, Franz S, et al. SLE--a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44:1101.</a></li><li><a class="nounderline abstract_t">Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997; 185:843.</a></li><li><a class="nounderline abstract_t">Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med 2009; 265:625.</a></li><li><a class="nounderline abstract_t">Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014; 1:e000056.</a></li><li><a class="nounderline abstract_t">Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202:1131.</a></li><li><a class="nounderline abstract_t">Mamula MJ. Lupus autoimmunity: from peptides to particles. Immunol Rev 1995; 144:301.</a></li><li><a class="nounderline abstract_t">Tsokos GC, Kovacs B, Sfikakis PP, et al. Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:600.</a></li><li><a class="nounderline abstract_t">Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694.</a></li><li><a class="nounderline abstract_t">Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152:1453.</a></li><li><a class="nounderline abstract_t">Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 1995; 181:1597.</a></li><li><a class="nounderline abstract_t">Azzouz D, Omarbekova A, Heguy A, et al. Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. Ann Rheum Dis 2019; 78:947.</a></li><li><a class="nounderline abstract_t">Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005; 17:518.</a></li><li><a class="nounderline abstract_t">Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93.</a></li><li><a class="nounderline abstract_t">Chabre H, Amoura Z, Piette JC, et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38:1485.</a></li><li><a class="nounderline abstract_t">Pisetsky DS. Autoantibodies and their significance. Curr Opin Rheumatol 1993; 5:549.</a></li><li><a class="nounderline abstract_t">Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997; 40:1374.</a></li><li><a class="nounderline abstract_t">Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995; 96:2990.</a></li><li><a class="nounderline abstract_t">Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8:1296.</a></li><li><a class="nounderline abstract_t">Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56:2344.</a></li><li><a class="nounderline abstract_t">Blomberg J, Nived O, Pipkorn R, et al. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations. Arthritis Rheum 1994; 37:57.</a></li><li><a class="nounderline abstract_t">Cooper GS, Dooley MA, Treadwell EL, et al. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002; 55:982.</a></li><li><a class="nounderline abstract_t">Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5:570.</a></li><li><a class="nounderline abstract_t">James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019.</a></li><li><a class="nounderline abstract_t">James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol 2012; 24:383.</a></li><li><a class="nounderline abstract_t">Sekigawa I, Kaneko H, Hishikawa T, et al. HIV infection and SLE: their pathogenic relationship. Clin Exp Rheumatol 1998; 16:175.</a></li><li><a class="nounderline abstract_t">Perl A, Fernandez D, Telarico T, Phillips PE. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol 2010; 22:483.</a></li><li><a class="nounderline abstract_t">Battaglia M, Garrett-Sinha LA. Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease. J Transl Autoimmun 2021; 4:100078.</a></li><li><a class="nounderline abstract_t">Lehmann P, Hölzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.</a></li><li><a class="nounderline abstract_t">Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.</a></li><li><a class="nounderline abstract_t">Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866.</a></li><li><a class="nounderline abstract_t">Ghaussy NO, Sibbitt WL Jr, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001; 28:2449.</a></li><li><a class="nounderline abstract_t">Parks CG, Cooper GS, Nylander-French LA, et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 2002; 46:1840.</a></li><li><a class="nounderline abstract_t">Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 2006; 15:728.</a></li><li><a class="nounderline abstract_t">Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:581.</a></li><li><a class="nounderline abstract_t">Finckh A, Cooper GS, Chibnik LB, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006; 54:3648.</a></li><li><a class="nounderline abstract_t">Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004; 50:849.</a></li><li><a class="nounderline abstract_t">Chiou SH, Lan JL, Lin SL, et al. Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus 2004; 13:442.</a></li><li><a class="nounderline abstract_t">Wang J, Kay AB, Fletcher J, et al. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis 2009; 68:345.</a></li><li class="breakAll">Stevens BE, Kamen DL. The environment and the host. In: Dubois' Lupus Erythematosus and Related Syndromes, 9th ed, Wallace D, Hahn B (Eds), Elsevier, 2018. p.86.</li><li><a class="nounderline abstract_t">Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41:1690.</a></li><li><a class="nounderline abstract_t">D'Andrea DM, Coupaye-Gerard B, Kleyman TR, et al. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996; 49:1214.</a></li><li><a class="nounderline abstract_t">Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94:4220.</a></li><li><a class="nounderline abstract_t">Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161:904.</a></li><li><a class="nounderline abstract_t">Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 1970; 49:1103.</a></li><li><a class="nounderline abstract_t">Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9:100.</a></li><li><a class="nounderline abstract_t">Davies KA, Peters AM, Beynon HL, Walport MJ. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 1992; 90:2075.</a></li><li><a class="nounderline abstract_t">Termaat RM, Assmann KJ, Dijkman HB, et al. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 1992; 42:1363.</a></li><li><a class="nounderline abstract_t">Schmiedeke TM, Stöckl FW, Weber R, et al. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 1989; 169:1879.</a></li><li><a class="nounderline abstract_t">Li QZ, Xie C, Wu T, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428.</a></li><li><a class="nounderline abstract_t">Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:3623.</a></li><li><a class="nounderline abstract_t">Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.</a></li><li><a class="nounderline abstract_t">Li JS, Liu MF, Lei HY. Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Clin Immunol Immunopathol 1996; 79:211.</a></li><li><a class="nounderline abstract_t">Reichlin M. Cell injury mediated by autoantibodies to intracellular antigens. Clin Immunol Immunopathol 1995; 76:215.</a></li><li><a class="nounderline abstract_t">McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50:1226.</a></li><li><a class="nounderline abstract_t">Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol 1993; 100:58S.</a></li><li><a class="nounderline abstract_t">Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992; 90:1067.</a></li><li><a class="nounderline abstract_t">Reefman E, Kuiper H, Jonkman MF, et al. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) 2006; 45:538.</a></li><li><a class="nounderline abstract_t">Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2014; 36:495.</a></li></ol></div><div id="topicVersionRevision">Topic 4669 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530651" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136143" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Understanding the epidemiology and progression of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33474834" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29251660" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology of systemic lupus erythematosus: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36241363" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920013" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16761508" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16761508" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406405" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rheumatic diseases in North America's indigenous peoples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473278" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidemiology of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655486" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Frequency of lupus in people of African origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19644962" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778212" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393454" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reproductive and menopausal factors and risk of systemic lupus erythematosus in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10503654" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of sex hormones in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253915" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent insights into the genetic basis of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16751355" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The epigenetic face of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153846" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sex differences in autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23434382" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Overexpression of X-linked genes in T cells from women with lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194860" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Estrogen in cardiovascular disease during systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25194860" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Estrogen in cardiovascular disease during systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6749396" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lupus in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6978135" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical features of systemic lupus erythematosus: differences related to race and age of onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17471524" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327845" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2302266" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2317226" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951378" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Morbidity of systemic lupus erythematosus: role of race and socioeconomic status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747764" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7511019" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Ethnic and geographic perspectives in SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7704008" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19946032" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Review: Male systemic lupus erythematosus: a review of sex disparities in this disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479324" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2648578" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6225928" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic lupus erythematosus in males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2319521" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039119" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2803325" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525847" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008925" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32151092" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204098" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493061" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Review of recent genome-wide association scans in lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18204448" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23917156" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Advances in lupus genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478477" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19851445" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846760" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22889593" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The genetics of type I interferon in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28085900" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109131" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27040498" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18668568" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759295" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468661" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887967" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : TLR7 ligands induce higher IFN-alpha production in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19019891" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16482158" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503323" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29775752" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374884" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dissecting complex epigenetic alterations in human lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070646" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070646" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446742" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The applied basic research of systemic lupus erythematosus based on the biological omics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719445" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21379322" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26798662" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27693588" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Genetics of human lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27497259" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338677" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25338677" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31710572" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : APOL1 and Kidney Disease: From Genetics to Biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16027372" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981062" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22041580" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846340" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Epigenetics in the pathogenesis of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37011055" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Higher Genetic Risk Loads Confer More Diverse Manifestations and Higher Risk of Lupus Nephritis in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12905462" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Sex hormones and systemic lupus erythematosus: review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320320" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pituitary hormones and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15968009" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354891" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Combined oral contraceptives in women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354890" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A trial of contraceptive methods in women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763408" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Menopause hormonal therapy in women with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155581" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Modulation of autoimmune rheumatic diseases by oestrogen and progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7656468" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Estrogens, the immune response and autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539705" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hormonal regulation of B-cell function and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16724801" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Sex hormones and SLE: influencing the fate of autoreactive B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2282655" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Sex hormones and the immune system--Part 1. Human data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24495300" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/156222" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1805860" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The possible role of prolactin in autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918240" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3664160" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The association of autoimmune thyroiditis with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10782814" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616885" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888073" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126985" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Cellular and molecular mechanisms of regulation of autoantibody production in lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27506962" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Laboratory testing for the diagnosis, evaluation, and management of systemic lupus erythematosus: Still more questions for the next generations: A Tribute and Thanks and in Memory of my mentor: Henry G. Kunkel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8519610" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Autoantibodies in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18305268" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561795" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Development of autoantibodies before the clinical onset of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524507" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Autoimmune disease. A problem of defective apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093826" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Sources of autoantigens in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479824" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30123218" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Follicular Helper T Cells in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868033" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868033" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23594005" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Belimumab for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29058308" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19854711" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30770544" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Immune cell metabolism in autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32826478" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Immunometabolism in the pathogenesis of systemic lupus erythematosus: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29739666" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Metabolism as a Target for Modulation in Autoimmune Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16447217" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The type I interferon system in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12642603" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15593221" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604793" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16947629" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693194" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The interferon-alpha signature of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25445206" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Interferon regulatory factors: critical mediators of human lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27694630" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16642019" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469140" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746906" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512812" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277168" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7718004" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22129255" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1975176" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859347" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896281" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : B cell receptor signaling in human systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000207" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Emerging and critical issues in the pathogenesis of lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721908" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Altered T and B lymphocyte signaling pathways in lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101889" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8824706" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Insights into the basis of systemic lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438836" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841182" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7586730" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Lupus: key pathogenic mechanisms and contributing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846493" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A critical role for complement in maintenance of self-tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738055" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Defective B cell tolerance checkpoints in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18613835" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19714604" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296403" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22383797" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12431669" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Systemic lupus erythematosus and microchimerism in autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23672591" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18597405" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26118732" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658004" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33394603" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Update on the cellular pathogenesis of lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529364" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18698174" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : The role of innate immunity in autoimmune tissue injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16778043" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Immunology. Discriminating microbe from self suffers a double toll.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075805" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17295441" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Toll-like receptor expression in lupus peripheral blood mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160420" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668740" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276080" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20559388" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20110525" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916843" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The complex role of DNA, histones and HMGB1 in the pathogenesis of SLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360203" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : HMGB1: a dangerous player in lupus pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27576056" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014673" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9485078" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9485079" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480659" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Defective waste disposal: does it induce autoantibodies in SLE?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683667" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919679" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928001" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : SLE--a disease of clearance deficiency?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9120390" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19493056" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Autoantigens in systemic autoimmunity: critical partner in pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25396070" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230478" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7590818" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Lupus autoimmunity: from peptides to particles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630108" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Defective antigen-presenting cell function in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371509" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301145" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : B cells process and present lupus autoantigens that initiate autoimmune T cell responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722439" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30782585" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093827" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Immune cells and cytokines in systemic lupus erythematosus: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2646863" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575698" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8398606" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Autoantibodies and their significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9259415" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Self antigens and epitope spreading in systemic autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675671" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8001742" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Idiotypic induction of autoimmunity: a new aspect of the idiotypic network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599763" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7510483" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12464374" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7691138" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : B-cell and T-cell function in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399948" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504579" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Lupus and Epstein-Barr.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9536396" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : HIV infection and SLE: their pathogenic relationship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644481" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Endogenous retroviral pathogenesis in lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33490939" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179293" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7511686" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8675699" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11708417" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12124868" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153843" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16150789" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075811" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022327" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15303571" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Pet dogs owned by lupus patients are at a higher risk of developing lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408249" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Alcohol consumption is not protective for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18408249" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Alcohol consumption is not protective for systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501424" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8731084" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590067" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4174454" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4987169" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2203588" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430231" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1474767" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2732675" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16322790" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075807" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2971836" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Determinants of immune complex-mediated glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635277" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554441" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Cell injury mediated by autoantibodies to intracellular antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077305" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8093710" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Pathomechanisms of photosensitive lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1522215" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16352635" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25102991" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
